Advertisement
Kinnate Biopharma Inc. (KNTE)
Kinnate Biopharma Statistics
Share Statistics
Kinnate Biopharma has 47.17M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 47.17M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 22.68M |
| Failed to Deliver (FTD) Shares | 116.75K |
| FTD / Avg. Volume | 31.8% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -0.98 and the forward PE ratio is null. Kinnate Biopharma's PEG ratio is 0.15.
| PE Ratio | -0.98 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | 0.69 |
| P/FCF Ratio | -1.1 |
| PEG Ratio | 0.15 |
Enterprise Valuation
Kinnate Biopharma has an Enterprise Value (EV) of 56.56M.
| EV / Sales | 0 |
| EV / EBITDA | -0.48 |
| EV / EBIT | -0.57 |
| EV / FCF | -0.57 |
Financial Position
The company has a current ratio of 13.19, with a Debt / Equity ratio of 0.02.
| Current Ratio | 13.19 |
| Quick Ratio | 13.19 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | -0.03 |
| Debt / FCF | -0.03 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is -70.7% and Return on Invested Capital is -73.23%.
| Return on Equity | -70.7% |
| Return on Assets | -64.89% |
| Return on Invested Capital | -73.23% |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1.34M |
| Employee Count | 84 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 0% in the last 52 weeks. The beta is 1.34, so Kinnate Biopharma's price volatility has been higher than the market average.
| Beta | 1.34 |
| 52-Week Price Change | 0% |
| 50-Day Moving Average | 2.49 |
| 200-Day Moving Average | 2.27 |
| Relative Strength Index (RSI) | 62.67 |
| Average Volume (20 Days) | 367.16K |
Income Statement
| Revenue | n/a |
| Gross Profit | -799K |
| Operating Income | -119.01M |
| Net Income | -112.65M |
| EBITDA | -118.21M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -2.42 |
Balance Sheet
The company has 57M in cash and 3.17M in debt, giving a net cash position of 53.82M.
| Cash & Cash Equivalents | 57M |
| Total Debt | 3.17M |
| Net Cash | 53.82M |
| Retained Earnings | -372.01M |
| Total Assets | 173.6M |
| Working Capital | 146.18M |
Cash Flow
In the last 12 months, operating cash flow was -100.04M and capital expenditures 0, giving a free cash flow of -100.04M.
| Operating Cash Flow | -100.04M |
| Capital Expenditures | 0 |
| Free Cash Flow | -100.04M |
| FCF Per Share | -2.15 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
KNTE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -102.05% |
| FCF Yield | -90.63% |
Analyst Forecast
Currently there are no analyst rating for KNTE.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | 0.96 |
| Piotroski F-Score | 2 |